Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xoma down on Phase II acne results

XOMA was off $1.23 (35%) to $2.27 on 6.6 million

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE